News

The deal is said to leverage TScan’s advanced platform to discover novel cancer antigens, which are expected to be targeted by TCR-based therapies. TScan chief scientific officer Gavin

The Chinese biopharmaceutical company said that it has been developing the COVID-19 vaccine candidate since January 2020. The firm claimed that its scientists have quickly completed comprehensive preclinical

The program will evaluate the safety and efficacy of Intensity’s lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral

According to the FDA, Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical

The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley

In this regard, Hope Biosciences will be evaluating the safety and efficacy of its adipose-derived mesenchymal stem cells (HB-adMSCs) in the mid-stage clinical trial. The phase 2 trial,

“We are thankful to the amazing team at MHRA for the careful and expeditious consideration that led to clearance of our application,” said Dr. Wayne Holman, Co-Founder of Ridgeback

ASC09 has an unprecedented high genetic barrier to resistance and has completed Phase I and Phase IIa clinical trials, which have shown potent anti-viral activity. Previous clinical trials

As part of the deal, Alnylam will secure up to $2bn from Blackstone for the advancement of its RNAi medicines, which are believed to have the potential to